Tumor antigen peptide-HLA complex

The Tumor antigen peptide-HLA complex is a structure formed when a peptide derived from a tumor-associated antigen is bound by a human leukocyte antigen (HLA) molecule—commonly a class I or class II MHC protein—and presented on the cell surface. This complex allows cytotoxic T lymphocytes to recognize and potentially eliminate tumor cells, forming the molecular basis for many cancer immunotherapies, including peptide vaccines and checkpoint inhibitors. HLA molecules are highly polymorphic, which influences both antigen presentation and immune response efficacy[2][3]. Tumor cells can evade immune recognition through loss or mutation of HLA or antigen presentation machinery[2][4]. Specific peptide-HLA complexes (such as MART-1/HLA-A2) serve as biomarkers and therapeutic targets in cancer[1].

Other names

Peptide-MHC complexPeptide-HLA complexpMHCTumor antigen-MHC complex

Activation of cytotoxic T cell response by presentation of tumor-specific antigen peptides via HLA molecules Immune system engagement in recognition and elimination of tumor cells